SIGA Technologies, Inc. recently appointed Dr. Phil Gomez as the company’s new CEO.
“I am so pleased to be joining SIGA at such an exciting time for the company,” Gomez said. “I look forward to working with Eric and the entire SIGA team to continue to grow our company and deliver our smallpox anti-viral treatment to our partners in government, as well as the public health and business communities.”
Current CEO Dr. Eric Rose will shift to become SIGA’s executive chairman of the board of directors. Rose has served as chairman of the board since 2007.
“I am proud to have led this extraordinary team who sets the standard for quality, innovation, and effectiveness in the field of smallpox anti-viral treatment,” Rose said. “I look forward to continuing to work with SIGA’s world class executive team, scientists and staff to advance our trials, support our customers and grow our company.”
Prior to his new appointment, Gomez served as a principal at PricewaterhouseCoopers (PwC) in its pharma and life sciences management and consulting practice. While at PwC, Gomez led the development and execution of business strategies for leading pharmaceutical companies. He also focused on enhancing operating models for drug development, new corporate strategies for research and development, and enabling clients to expand opportunities in the global vaccine market.